Kallikrein Inhibitors [MoA]: Side Effects & Safety Data for 4 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Kallikrein Inhibitors [MoA] includes 4 drugs with a combined 18,156 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
4
Drugs in Class
18,156
Combined Reports
All Kallikrein Inhibitors [MoA] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| HUMAN C1-ESTERASE INHIBITOR | Cinryze | 14,344 | 1,403 | 3,966 | 9.8% |
| LANADELUMAB | TAKHZYRO | 2,058 | 109 | 1,007 | 5.3% |
| ECALLANTIDE | Kalbitor | 1,206 | 23 | 499 | 1.9% |
| BEROTRALSTAT | Orladeyo | 548 | 24 | 128 | 4.4% |
Common Side Effects in Kallikrein Inhibitors [MoA] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Hereditary angioedema | 7,558 | 76 |
| Off label use | 1,836 | 814 |
| No adverse event | 1,699 | 59 |
| Drug ineffective | 1,680 | 525 |
| Weight increased | 1,306 | 431 |
| Product dose omission issue | 1,265 | 20 |
| Intentional product use issue | 1,125 | 535 |
| Product use in unapproved indication | 1,034 | 505 |
| Product use issue | 976 | 313 |
| Weight decreased | 956 | 73 |